Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007112 (prostatic adenocarcinoma)
 2,574 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A total of 25 patients with histologically proved adenocarcinoma of the prostate, whose disease was staged clinically as D2 by appropriate radiographic and nuclear medicine studies, received increasing doses of PAY 276, an antiprostatic acid phosphatase monoclonal antibody for radioimmunological imaging. The patients were divided into 5 groups of 5. Groups 1 through 5 received an infusion of 5, 10, 20, 40 or 80 mg. monoclonal antibody, respectively, 1 mg. of which was labeled to 5 mCi. of 111indium, while stable monoclonal antibody was added to achieve the desired antibody concentration. No patient had an allergic reaction, and no significant change in serial hemoglobin levels, platelet count, chemistry profile or results of urinalyses was noted. The monoclonal antibody scan visualized at least 1 lesion in 19 of 25 patients (76 per cent): 4 in groups 1 and 2, and all 15 in groups 3 to 5. With results of conventional radiography and bone scintigraphy considered definitive for metastases, monoclonal antibody scans detected 7 of 32 metastases (21.8 per cent) in group 3 (20 mg.), 31 of 58 (53.4 per cent) in group 4 (40 mg.) and 101 of 134 (75.4 per cent) in group 5 (80 mg). In group 5 the incidence of false positive and false negative scans was 2.3 per cent (3 of 132) and 24.6 per cent (33 of 134), respectively. The detection of metastatic lesions increased as the concentration of unlabeled monoclonal antibody increased. Radioimmunological imaging of prostatic cancer with antiprostatic acid phosphatase monoclonal antibody seems to be feasible.
 ...
PMID:Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276. 382 Mar 71

At the close of each decade, we are reminded by medical statisticians that our longevity increases significantly. For the male, especially if he be of black race this statement has an ironic twist. Over age 70, prostatic "cancer" assumes the leadership list of "cancers" in general, supplanting lung and colo-rectal. One interesting point evolved by careful autopsy studies suggests that this incidence is found coincidentally and is not primarily responsible for the cause of death. This illustrates a different significance to other neoplasia, and offers useful opportunities to study the evolution of a neoplasm. In contrast to other "cancers" (for example pulmonary), the histological nature of the tumor is almost totally derived from the acinar lobules and designated adenocarcinoma. Neoplasia arising from the fibromuscular stroma (sarcoma) and metaplastic ductus (squamous cell carcinoma) constitute less than 1% of all prostate cancers. Histological appearances, however, are not as simple as hoped. As in many tumors the section may present a uniform well-differentiated adenocarcinoma in which the acinar structure is well maintained--yet at the opposing end of the spectrum show a fatally dedifferentiated picture whose organ origin is difficult to determine. Adding to the complication is the wide variation, far more commonly seen, of the mixed tumor with all variations presenting a composite panorama of histology. Indeed the pure type is rare. As with all neoplastic disease, early detection is critical, since opportunity for cure with the various forms of therapy from surgery through radiation to chemotherapy are increasing rapidly. The prostate gland is relatively accessible to the trained finger of the physician and later stages of the disease are palpable. However, the earliest Stage (I) is not discovered by rectal examination, hence provides an ideal opportunity for the serum tumor marker, to identify disease. Since 1938, disseminated prostatic adenocarcinoma has been associated with elevation of activity of an enzyme acid phosphatase. Although there are several isoenzymes the prostatic specific one has in the past been assayed by different spectrophotometric techniques using selective substrate and chemical inhibition. More recently various immunological methods have added a greater sensitivity and specificity to the early detection of prostatic adenocarcinoma. However is should be clearly stated that prostatic acid phosphatase is not cancer specific and can be associated with other nonmalignant lesions in the prostate gland.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:The laboratory diagnosis of prostatic adenocarcinoma. 614 53

We measured the concentrations of creatine kinase B-isoenzymes by radioimmunoassay in 271 serum specimens from patients with azotemia, benign prostatic hyperplasia, adenocarcinoma of the prostate, and transitional cell carcinoma of the bladder. There was no correlation between the concentrations of B-isoenzymes and creatinine in the sera of azotemic patients. Above-normal concentrations of B-isoenzymes were found in sera from three patients with acute renal failure, but in only two of 28 specimens from patients with chronic renal failure. Above-normal concentrations of B-isoenzymes also were found in sera from three of 18 patients with untreated carcinoma of the prostate, 10 of 25 patients with treated carcinoma, 20 of 135 patients with benign prostatic hyperplasia, and 10 of 33 patients and with transitional cell carcinoma of the bladder. An above-normal concentration of B-isoenzymes in serum has a low predictive value for adenocarcinoma of the prostate, was not a sensitive indicator of the presence of carcinoma, and was noted paradoxically in six patients with treated carcinoma who had normal acid phosphatase activities in serum. We conclude that routine measurement of B-isoenzymes is not useful to establish the diagnosis of adenocarcinoma of the prostate.
 ...
PMID:Radioimmunoassay of creatine kinase B-isoenzymes in serum of patients with azotemia, obstructive uropathy, or carcinoma of the prostate or bladder. 615 95

The clinical value of prostate acid phosphatase (PAP) measurements in the bone marrow aspirate of patients with prostatic adenocarcinoma has been unclear. Using a radioimmunoassay (RIA) to measure PAP, we have evaluated this potential indicator of occult metastases in 127 controls and in 300 patients with prostatic adenocarcinoma. Elevations of the tumor marker were found in 9%, 10%, 19%, and 82% of patients with stages B, C, D1, and D2 adenocarcinoma respectively. Clinical follow-up ranging from 7 to 43 months (average 23 months) was available for 97 patients without any initial indication of metastasis by bone scan. In this group 11 patients had elevated levels of bone marrow acid phosphatase (BMAP) by RIA and four developed radiological evidence of bone metastasis 21-25 months following initial staging. However, only three of the 86 patients with normal BMAP levels have developed bone metastasis. Our results indicate that measurement of bone marrow PAP by immunological methods has prognostic significance. Dilution of the bone marrow aspirate by peripheral blood, however, may limit the application of this technique.
 ...
PMID:Radioimmunoassay of bone marrow prostatic acid phosphatase. 616 77

The localization and distribution of prostatic specific acid phosphatase (PSAP) in normal, hyperplastic and neoplastic prostates were studied by specific immunohistochemical of normal and hyperplastic prostates. In adenocarcinoma of the prostate, a correlation of the PSAP staining with the degree of differentiation and the ability of the tumor to form a gland was observed: more intense and uniform staining in well differentiated tumors and less intense and more variable stains in poorly differentiated tumors. The same correlation was also observed in tumors metastasized to lymph nodes and other organs.
 ...
PMID:Immunohistochemical identification of prostatic acid phosphatase: correlation of tumor grade with acid phosphatase distribution. 617 41

Prostatic specific acid phosphatase and prostatic specific antigen have been used as specific markers of prostatic adenocarcinoma in immunohistochemical studies, particularly when seeking the primary site of a poorly differentiated metastasis. We herein evaluate the effect of therapy on the persistence of these markers in surgically obtained tissues. Prostatic biopsies from 30 patients with adenocarcinoma of the prostate gland before and after treatment with orchiectomy alone, diethylstilbestrol, external beam radiation or combined radiation and diethylstilbestrol were studied for prostatic specific acid phosphatase and prostatic specific antigen using the indirect immunoperoxidase technique. The interval between biopsies ranged from 3 to 72 months, with an average of 28 months. All pre-treatment biopsies stained positively for prostatic specific acid phosphatase and prostatic specific antigen. Staining for prostatic specific antigen and prostatic specific acid phosphatase was seen easily in 29 of 30 post-treatment biopsies, while in 1 case infiltrating anaplastic cells surrounded by stroma showed staining for these antigens in an extremely small percentage of cells, which were overlooked easily unless examined carefully. In view of this small number of positively staining cells this case was designated as equivocal. While some cases demonstrated less intense staining in post-treatment biopsies compared to pre-treatment, this finding was by no means constant. With these primary antisera a higher percentage of cytologically malignant cells stained positively for prostatic specific acid phosphatase than for prostatic specific antigen in adjacent tissue sections in some cases. Prostatic specific acid phosphatase and prostatic specific antigen appear to be sensitive and persistent markers of prostatic adenocarcinoma despite morphologic changes accompanying various therapies.
 ...
PMID:Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry. 619 Oct 50

A series of 60 cases of prostatic adenocarcinoma and 34 cases of benign prostatic hyperplasia were examined quantitatively after immunoperoxidase staining for prostate-specific antigen (PSA), prostate-specific acid phosphatase (PSAP), carcino-embryonic antigen (CEA), epithelial membrane antigen (EMA), alpha fetoprotein (AFP), and human chorionic gonadotrophin (HCG). The tumors were graded I to IV according to the MDAH grading system recently proposed. Fifty-nine of the 60 tumors were positive for PSA and 58 were positive for PSAP. The one PSA and PSAP negative case was CEA negative and weakly EMA positive. Grade I to III tumors stained more tumor cells and more diffusely for PSA and PSAP than grade IV tumors. There was no significant difference in the intensity or extent of staining between grade I and grade II-III tumors for PSA and PSAP. A comparison of PSA and PSAP showed that PSA stained more intensely and more extensively than PSAP. Benign prostatic tissue and low-grade prostatic tumors did not stain for CEA but three of the 20 grade IV tumors and one of the 23 grade II-III tumors did. Staining for EMA was focal and showed no relation to tumor grade. Benign and malignant lesions failed to stain for AFP and HCG.
 ...
PMID:Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. 619 66

On the basis of a series of 89 patients with a histologically confirmed adenocarcinoma of the prostate and another population of 89 patients with prostatic hypertrophy, also confirmed histologically, the authors study the sensitivity and specificity of the radio-immunological estimation of prostatic acid phosphatase levels. Comparison is made of the performance of radio-immunological techniques with that of conventional techniques. As a general rule, the sensitivity of the test is very low, since amongst 39% of the prostatic carcinomas studied, the RI acid phosphatase level was below the upper limit of normal fixed at 3.2 ng/ml. By contrast, the degree of specificity is high, since amongst 96% of cases with abnormally high RI acid phosphatase levels, the diagnosis was indeed an adenocarcinoma of the prostate. In terms of stages, sensitivity was found to be nil for minor stages T1 - T2 and of the order of 80% for advanced stages. This confirmed data from the literature. In the absence of bone metastases detectable radiologically or by isotope bone scan, an abnormally high RI acid phosphatase level is predictive of lymph node involvement in 90% of cases. By contrast, under the same conditions of bone investigations, a normal RI acid phosphatase level corresponds in 81% of cases with absence of lymph node involvement and in 19% with limited involvement. In patients with value which are normal or become normal under the influence of treatment, the prognosis is better than if such does not apply. Finally, figures given by radioimmunological estimation are much more specific than those obtained by traditional enzyme estimations.
 ...
PMID:[Role of prostatic acid phosphatases in the treatment of adenocarcinoma of the prostate]. 620

During the course of another investigation, three dogs had been castrated 3 months previously. Upon completion of the experiment, it was discovered that one dog presented a spontaneous prostatic adenocarcinoma of intraalveolar proliferative type at histology. Prostate weight of this dog before castration was estimated to be 22 g by tridimensional measurement at laparotomy and remained relatively constant (19 g) 3 months after castration. These results indicate that if regression had occurred in some cell populations (androgen-dependent) it was only partial and masked by growth of androgen-independent cells. Analysis of 12 individual steroids in peripheral blood and in prostatic tissue attested of a normal adrenal secretory activity. A series of 15 hydrolytic enzymes along with receptors for androgen, estrogen, and progesterone, were determined in prostatic tissue obtained at sacrifice. Enzymatic activities were those of typical epithelial cells, and most of them remained relatively high despite low levels of circulating testosterone. However, two markers of androgen action in dog prostate, acid phosphatase and arginine esterase, were significantly reduced. Receptor levels were similar to those of castrated animals. Thus, cancer cells had probably retained some androgen sensitivity.
 ...
PMID:Single case report of prostate adenocarcinoma in a dog castrated three months previously. Morphological, biochemical, and endocrine determinations. 620 17

Small cell carcinomas of the prostate are rare. A few reported cases have manifested morphologic and functional neuroendocrine characteristics, and it has been suggested that these tumors are derived from the argentaffinic/argyrophilic cells normally present in the prostate. The authors have recently studied three cases of primary prostatic small cell carcinoma in which the small cell component developed during the course of progression of "regular" prostatic adenocarcinoma, and reflected a terminal aggressive phase of the disease. Immunoperoxidase staining for prostate-specific acid phosphatase (PSAP) showed positivity in the adenocarcinoma but absence in the small cell component of each tumor. The association of small cell carcinoma with prostatic adenocarcinoma indicates that in considering the histogenesis of prostatic small cell carcinoma, a specific neuroendocrine cell of origin need not be implicated.
 ...
PMID:The histogenesis of small cell carcinoma of the prostate. An immunohistochemical study. 632 85


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>